Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients

Ji, Dengbo; Qiao, Meng; Yao, Yunfeng; Li, Ming; Chen, Hailong; Dong, Qi; Jia, Jinying; Cui, Xinxin; Li, Zhaowei; Xia, Jinhong; Gu, Jin

doi:10.1016/j.ebiom.2018.08.042

Title: Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients

Full Record
Other Related Research

Authors:: Ji, Dengbo; Qiao, Meng; Yao, Yunfeng; Li, Ming; Chen, Hailong; Dong, Qi; Jia, Jinying; Cui, Xinxin; Li, Zhaowei; Xia, Jinhong; Gu, Jin

Publication Date:: 2018-09-01

Sponsoring Org.:: USDOE Office of Electricity (OE), Advanced Grid Research & Development. Power Systems Engineering Research

OSTI Identifier:: 1466868

Grant/Contract Number:: No.2012AA02A506, 2014AA020801

Resource Type:: Published Article

Journal Name:: EBioMedicine

Additional Journal Information:: Journal Name: EBioMedicine Journal Volume: 35 Journal Issue: C; Journal ID: ISSN 2352-3964

Publisher:: Elsevier

Country of Publication:: Netherlands

Language:: English

Citation Formats


                    Ji, Dengbo, Qiao, Meng, Yao, Yunfeng, Li, Ming, Chen, Hailong, Dong, Qi, Jia, Jinying, Cui, Xinxin, Li, Zhaowei, Xia, Jinhong, and Gu, Jin. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.  Netherlands: N. p., 2018. 
Web.  doi:10.1016/j.ebiom.2018.08.042.

Copy to clipboard


                    Ji, Dengbo, Qiao, Meng, Yao, Yunfeng, Li, Ming, Chen, Hailong, Dong, Qi, Jia, Jinying, Cui, Xinxin, Li, Zhaowei, Xia, Jinhong, & Gu, Jin. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.  Netherlands.  https://doi.org/10.1016/j.ebiom.2018.08.042

Copy to clipboard


                    Ji, Dengbo, Qiao, Meng, Yao, Yunfeng, Li, Ming, Chen, Hailong, Dong, Qi, Jia, Jinying, Cui, Xinxin, Li, Zhaowei, Xia, Jinhong, and Gu, Jin. Sat .  
"Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients".  Netherlands.  https://doi.org/10.1016/j.ebiom.2018.08.042.

Copy to clipboard


                    
@article{osti_1466868,

  title        = {Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients},

  author       = {Ji, Dengbo and Qiao, Meng and Yao, Yunfeng and Li, Ming and Chen, Hailong and Dong, Qi and Jia, Jinying and Cui, Xinxin and Li, Zhaowei and Xia, Jinhong and Gu, Jin},

  abstractNote = {},

  doi          = {10.1016/j.ebiom.2018.08.042},

  journal      = {EBioMedicine},

  number       = C,

  volume       = 35,

  place        = {Netherlands},

  year         = {2018},

  month        = {9}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Publisher's Version of Record
https://doi.org/10.1016/j.ebiom.2018.08.042

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 5 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Cancer genomics predicts disease relapse and therapeutic response to neoadjuvant chemotherapy of hormone sensitive breast cancers

Journal Article Zhu, Jieqiang ; Muskhelishvili, Levan ; Tong, Weida ; ... - Scientific Reports

Several studies provide insight into the landscape of breast cancer genomics with the genomic characterization of tumors offering exceptional opportunities in defining therapies tailored to the patient’s specific need. However, translating genomic data into personalized treatment regimens has been hampered partly due to uncertainties in deviating from guideline based clinical protocols. Here we report a genomic approach to predict favorable outcome to treatment responses thus enabling personalized medicine in the selection of specific treatment regimens. The genomic data were divided into a training set of N = 835 cases and a validation set consisting of 1315 hormone sensitive, 634 triplemore »« less
https://doi.org/10.1038/s41598-020-65055-4

Full Text Available
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

Journal Article Nakamura, Yoshiaki ; Yamanaka, Takeharu ; Chin, Keisho ; ... - Annals of Surgical Oncology (Online)

Background: Two phase 2 trials of oxaliplatin-containing adjuvant therapy for patients with gastric cancer (GC) after D2 gastrectomy were conducted in Japan. The SOXaGC trial evaluated the tolerability and safety of adjuvant therapy with S-1 plus oxaliplatin (SOX), whereas the J-CLASSIC trial evaluated the feasibility of adjuvant therapy with capecitabine plus oxaliplatin (CAPOX). Because both were studies that did not evaluate survival results as study end points, the authors evaluated the survival outcomes for the patients in the two trials. Methods: All 62 and 100 patients in the full analysis set of the SOXaGC and J-CLASSIC trials, respectively, were includedmore »« less
https://doi.org/10.1245/S10434-018-7063-8
Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes

Journal Article Kishan, Amar U. ; Wang, Pin-Chieh ; Sharif, Jamal ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To assess the magnitude and predictors of patient-reported fatigue among breast cancer patients receiving radiation therapy (RT). Methods and Materials: Patients receiving breast RT completed a survey querying fatigue at each weekly on-treatment visit. Patient-reported fatigue severity and interference was assessed on an ordinal scale of 0 to 4, using a validated scoring system. Baseline anxiety and depression scores were also obtained. The kinetics of mean fatigue scores per week and the maximum fatigue scores over the course of the entire treatment were assessed, and clinical predictors were identified by univariate and multivariate regression. Results: The average fatigue severitymore »« less
https://doi.org/10.1016/J.IJROBP.2016.01.062
Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials

Journal Article Creutzberg, Carien L., E-mail: c.l.creutzberg@lumc.nl ; Stiphout, Ruud G.P.M. van ; Nout, Remi A. ; ... - International Journal of Radiation Oncology, Biology and Physics

Background: Postoperative radiation therapy for stage I endometrial cancer improves locoregional control but is without survival benefit. To facilitate treatment decision support for individual patients, accurate statistical models to predict locoregional relapse (LRR), distant relapse (DR), overall survival (OS), and disease-free survival (DFS) are required. Methods and Materials: Clinical trial data from the randomized Post Operative Radiation Therapy for Endometrial Cancer (PORTEC-1; N=714 patients) and PORTEC-2 (N=427 patients) trials and registered group (grade 3 and deep invasion, n=99) were pooled for analysis (N=1240). For most patients (86%) pathology review data were available; otherwise original pathology data were used. Trial variablesmore »« less
https://doi.org/10.1016/J.IJROBP.2014.11.022
Use of Molecular Imaging to Predict Clinical Outcome in Patients With Rectal Cancer After Preoperative Chemotherapy and Radiation

Journal Article Konski, Andre ; Tianyu, Li ; Sigurdson, Elin ; ... - International Journal of Radiation Oncology, Biology and Physics

Purpose: To correlate changes in 2-deoxy-2-[18F]fluoro-D-glucose (18-FDG) positron emission tomography (PET) (18-FDG-PET) uptake with response and disease-free survival with combined modality neoadjuvant therapy in patients with locally advanced rectal cancer. Methods and Materials: Charts were reviewed for consecutive patients with ultrasound-staged T3x to T4Nx or TxN1 rectal adenocarcinoma who underwent preoperative chemoradiation therapy at Fox Chase Cancer Center (FCCC) or Robert H. Lurie Comprehensive Cancer Center of Northwestern University with 18-FDG-PET scanning before and after combined-modality neoadjuvant chemoradiation therapy . The maximum standardized uptake value (SUV) was measured from the tumor before and 3 to 4 weeks after completion ofmore »« less
https://doi.org/10.1016/j.ijrobp.2008.07.050

Similar Records